ea0089c8 | Clinical – Chemo/SSA/Biologics | NANETS2022
Al-Toubah, MPH Taymeyah
, Morse, MD Brian
, Haider, MD Mintallah
, Valone, PA Tiffany
, Strosberg, MD Jonathan
Background: Immune checkpoint inhibitors have not been shown to be active in well-differentiated NETs, with response rates <5%. Lenvatinib is a multitargeted TKI which targets VEGF and FGF receptors and has been reported to be effective in pancreatic and gastrointestinal NETs (40% and 18.5% ORR, respectively). The combination of antiangiogenic and checkpoint inhibitor therapies can be synergistic in other cancers. We therefore evaluated the combination of lenvatinib and pe...